

Supplementary Materials

Table S1. Risk factors associated with treatment outcome of solitary plasmacytoma treated with RT (univariate analysis)

	n	5-year LC (%)	p-value	5-year MMFS (%)	p-value	5-year FFS (%)	p-value	5-year OS (%)	p-value
Age (yr)									
<60	22	77.2	0.230	36.4	0.820	37.7	0.840	88.8	0.320
≥60	25	95.5		38.8		36.9		76.5	
Sex									
Male	30	78.6	0.110	36.5	0.620	36.5	0.440	87.2	0.190
Female	17	100.0		41.0		41.0		74.0	
Tumor location									
Extramedullary	11	100.0	0.220	100.0	0.001	100.0	<0.001	90.9	0.430
Bone	36	82.0		21.5		21.3		78.8	
Tumor size (cm)									
<5	20	95.0	0.490	68.4	0.004	64.6	0.007	87.8	0.470
≥5	21	88.0		16.9		17.2		74.3	
Serum M protein present									
No	16	87.5	0.230	49.1	0.210	49.1	0.088	85.1	0.960
Yes	20	82.0		21.1		22.2		85.9	
Unknown	11	100.0		45.5		45.5		72.7	
Bence Jones proteinuria									
Absent	28	85.9	0.650	34.1	0.200	35.1	0.320	87.2	0.960
Present ^{a)}	5	100.0		40.0		40.0		100.0	
Unknown	14	84.6		47.6		43.7		69.2	
Serum free light chain ratio									
Normal	9	100.0	0.078	59.3	0.017	59.3	0.004	87.5	0.950
Abnormal ^{b)}	9	72.9		29.6		22.2		83.3	
Unknown	29	87.0		39.5		40.2		81.1	
RT dose									
<45 GyEQD2	31	85.9	0.920	35.6	0.800	34.7	0.620	84.8	0.590
≥45 GyEQD2	15	92.9		51.4		51.4		76.2	
Surgical intervention									
Yes	14	100.0	0.150	50.6	0.280	50.6	0.210	84.2	0.310
No	33	80.2		29.7		29.8		78.6	
Chemotherapy									
Yes	2	100.0	0.640	50.0	0.730	50.0	0.690	100.0	0.280
No	43	86.4		37.0		36.7		81.1	

RT, radiation therapy; LC, local control; MMFS, multiple myeloma-free survival; FFS, failure-free survival; OS, overall survival; EQD2, equivalent dose in 2-Gy fractions at α/β of 10.

^{a)}Two-year survival, ^{b)}3-year survival.